What is the main business of Graviti Polska?

The main business activity of Graviti Polska focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on December 5, 2016.

Where is the headquarters located?

The headquarters is located at: Aleje Jerozolimskie 85, 02-001 Warszawa.

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of $25,890, representing an increase of 38.2% compared to 2024.

Yes, the company recorded a net profit of $12,898 in 2025, meaning the company increased its profit by 64.0%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $5,432 in 2025, representing 48% of all operating expenses.

Graviti Polskasp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2016-12-05

Share capital

5,000.00 PLN

Registered address

Aleje Jerozolimskie 85/21, 02-001 Warszawa, Poland

Electronic delivery address

AE:PL-99316-58961-IEABE-30

Financials

Revenue history (in k)

Filing timeliness

5 of 6 financial statements were filed late (the longest delay 1372 days for 2021).

2025filed
202408/05/2026
202317/04/2026
202217/04/2026
202117/04/2026
202018/10/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Manufacture of pharmaceutical preparations160 / 185

Top 86%

Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations196 / 232

Top 84%

Sector · Manufacturing21,771 / 24,529

Top 89%

City · Warszawa44,774 / 57,092

Top 78%

Voivodeship · Mazowieckie61,890 / 77,295

Top 80%

Country · Poland243,552 / 298,580

Top 82%

Results vs industry

Revenue

This companyUSD 25.89kMedianUSD 919.05kAverageUSD 25.83m

Net profit

This companyUSD 12.90kMedianUSD 14.92kAverageUSD 2.77m

Operating costs

This companyUSD 11.34kMedianUSD 873.06kAverageUSD 21.42m

Assets

This companyUSD 96.88kMedianUSD 897.46kAverageUSD 31.52m

Industry

Manufacture of pharmaceutical preparations (21.20.Z)Primary
Manufacture of chemicals and chemical products (20)
Manufacture of basic pharmaceutical products (21.1)

Authorized Representatives

Karolina Krupaage 29 – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

Owner	Shares	Share value	Stake
Karolina Krupa-Gawełage 29	100	$1,350.62	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2016-12-10.

Bank Millennium
21 1160 2202 0000 0003 1691 4849

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Aug 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$1,282$1,282	Prezydent Miasta Stołecznego Warszawy

Competitors

Name	Revenue	Website
Anpharm Przedsiębiorstwo FarmaceutyczneS.A.	$111,469,394.21	anpharm.pl
Tarchomińskie Zakłady Farmaceutyczne PolfaS.A.	$102,988,448.02	polfa-tarchomin.com.pl
VercoS.A.	$43,577,172.02	verco.com.pl
MedicofarmaS.A.	$8,530,473.72	medicofarma.pl
VitamaS.A.	$4,287,087.38	vitama.pl
Munar PharmaS.A.	$85,649.72	munar.pl
Sanford Biotechsp. z o.o.	$2,586.64	sanfordbiotech.com
Cefeasp. z o.o.	$294.66	cefea.pl
Auxilius PharmaS.A.	$0.83	auxiliuspharma.com
Stg25Branch (foreign co.)	–	glagolica.eu